

Omicron: from Mild Flu to Full Bloom COVID?

By Mai Wang

Report Generated: February 9, 2022

Last Update: February 9, 2022 2:29pm

Sequence Source: NCBI GENBANK <https://www.ncbi.nlm.nih.gov/sars-cov-2/>

Software: GENEIDO 1.0

Software Functions: Pathogen genome analysis and symptom prediction from Rivermap Research & Consulting LLC (www.rivermapsolution.com)

Summary:

Note: Type S1, S2 and S3 had been renamed to GENEIDO Types GT-S1, GT-S2 and GT-S3.

1. An updated analysis of the genome sequences of SARS-CoV-2 shows that the Omicron variant now has all the THREE GENEIDO Types: GT-S1, GT-S2 and GT-S3. It suggests that the Omicron now could have all the original COVID-19 symptoms that involves Lung, Heart, Brain, CNS and other organs as suggested in earlier reports.
2. The Analysis:
 - a. 50 random sequences are picked from GENBANK, 25 from US (California, Florida, New York) and 25 from Japan
 - b. Collection Dates within January 2022
 - c. Variants: BA.1 (Japan 1, US 5), BA.1.1 (Japan 24, US 19), AY.44 (Japan 0, US 1)
3. Result:
 - a. US: GT-S1 0%, GT-S2 52%, GT-S3 48%
 - b. Japan: GT-S1 24%, GT-S2 44%, GT-S3 32%

Please see Table 1a and 1b below.

4. A quick summary of the key symptoms of each GENEIDO Type:

a. GT-S1:

- i. Fever
- ii. Myocarditis
- iii. Bleeding (rash, pink eyes etc.)
- iv. Muscle and joint pain
- v. Decrease in brain and CNS function

b. GT-S2:

- i. Fever, Frontal headache, sore throat
- ii. Dry skin and mucous
- iii. Decrease in brain and CNS function
- iv. Fatigue and/or muscle weakness

c. GT-S3:

- i. Lung problem: necrosis, difficulty in breathing, Lung edema, phlegm or pus
- ii. Necrosis of the inner linings of the respiratory or digestive tracts
- iii. Chill and shivering (mostly no fever)
- iv. Diarrhea or other digestive problems
- v. Sudden flaccid paralysis

For more detail symptom lists, please visit: <https://rivermapsolution.com/Sample-Reports/Comparison-S1-S2-S3-041520.pdf>

5. Prediction:

- a. The data tells us that the Omicron GT-S2 cases (For example: the original South Africa Omicron strain B.1.1.529) subsides from late January 2022, as predicted in the last report.
- b. Omicron GT-S3 cases will subside in May or June 2022.

6. Concern:

- a. **Would Omicron GT-S1 and Omicron GT-S3 lead to fast spreading AND severe conditions?**

SARS-CoV-2 Analysis January 2022 – US (CA, FL, NY)

GENBANK ID	Region	Collection Date	Variant	GENEIDO Type	URL
OM562195.1	US-FL	1/27/2022	BA.11	GT-S3	https://www.ncbi.nlm.nih.gov/nuccore/OM562195.1?report=fasta
OM562206.1	US-FL	1/27/2022	BA.11	GT-S3	https://www.ncbi.nlm.nih.gov/nuccore/OM562206.1?report=fasta
OM562038.1	US-FL	1/26/2022	BA.11	GT-S3	https://www.ncbi.nlm.nih.gov/nuccore/OM562038.1?report=fasta
OM562115.1	US-CA	1/26/2022	BA.11	GT-S3	https://www.ncbi.nlm.nih.gov/nuccore/OM562115.1?report=fasta
OM561427.1	US-NY	1/24/2022	BA.11	GT-S3	https://www.ncbi.nlm.nih.gov/nuccore/OM561427.1?report=fasta
OM564756.1	US-CA	1/24/2022	BA.11	GT-S3	https://www.ncbi.nlm.nih.gov/nuccore/OM564756.1?report=fasta
OM563800.1	US-NY	1/22/2022	AY.44	GT-S3	https://www.ncbi.nlm.nih.gov/nuccore/OM563800.1?report=fasta
OM563838.1	US-FL	1/22/2022	BA.11	GT-S3	https://www.ncbi.nlm.nih.gov/nuccore/OM563838.1?report=fasta
OM500741.1	US-CA	1/20/2022	BA.1	GT-S2	https://www.ncbi.nlm.nih.gov/nuccore/OM500741.1?report=fasta
OM500735.1	US-CA	1/20/2022	BA.11	GT-S2	https://www.ncbi.nlm.nih.gov/nuccore/OM500735.1?report=fasta
OM500718.1	US-FL	1/20/2022	BA.11	GT-S2	https://www.ncbi.nlm.nih.gov/nuccore/OM500718.1?report=fasta
OM500712.1	US-FL	1/20/2022	BA.11	GT-S2	https://www.ncbi.nlm.nih.gov/nuccore/OM500712.1?report=fasta
OM521367.1	US-NY	1/20/2022	BA.1	GT-S2	https://www.ncbi.nlm.nih.gov/nuccore/OM521367.1?report=fasta

OM521365.1	US-NY	1/20/2022	BA.11	GT-S2	https://www.ncbi.nlm.nih.gov/nuccore/OM521365.1?report=fasta
OM498593.1	US-NY	1/18/2022	BA.11	GT-S2	https://www.ncbi.nlm.nih.gov/nuccore/OM498593.1?report=fasta
OM498550.1	US-CA	1/18/2022	BA.11	GT-S2	https://www.ncbi.nlm.nih.gov/nuccore/OM498550.1?report=fasta
OM498548.1	US-CA	1/18/2022	BA.11	GT-S2	https://www.ncbi.nlm.nih.gov/nuccore/OM498548.1?report=fasta
OM498543.1	US-FL	1/18/2022	BA.11	GT-S2	https://www.ncbi.nlm.nih.gov/nuccore/OM498543.1?report=fasta
OM498540.1	US-NY	1/18/2022	BA.11	GT-S2	https://www.ncbi.nlm.nih.gov/nuccore/OM498540.1?report=fasta
OM450324.1	US-FL	1/14/2022	BA.11	GT-S3	https://www.ncbi.nlm.nih.gov/nuccore/OM450324.1?report=fasta
OM450374.1	US-NY	1/14/2022	BA.1	GT-S3	https://www.ncbi.nlm.nih.gov/nuccore/OM450374.1?report=fasta
OM450401.1	US-NY	1/14/2022	BA.1	GT-S3	https://www.ncbi.nlm.nih.gov/nuccore/OM450401.1?report=fasta
OM456081.1	US-CA	1/14/2022	BA.11	GT-S2	https://www.ncbi.nlm.nih.gov/nuccore/OM456081.1?report=fasta
OM456085.1	US-CA	1/14/2022	BA.11	GT-S2	https://www.ncbi.nlm.nih.gov/nuccore/OM456085.1?report=fasta
OM493038.1	US-FL	1/11/2022	BA.1	GT-S3	https://www.ncbi.nlm.nih.gov/nuccore/OM493038.1?report=fasta

Table 1a SARS-CoV-2 GENEIDO Analysis January 2022 - US

SARS-CoV-2 Analysis January 2022 - Japan

GENBANK ID	Region	Collection Date	Variant	GENEIDO Type	URL
BS002361.1	Japan	1/15/2022	BA.11	GT-S2	https://www.ncbi.nlm.nih.gov/nuccore/BS002361.1?report=fasta
BS002362.1	Japan	1/15/2022	BA.11	GT-S1	https://www.ncbi.nlm.nih.gov/nuccore/BS002362.1?report=fasta
BS002363.1	Japan	1/15/2022	BA.11	GT-S1	https://www.ncbi.nlm.nih.gov/nuccore/BS002363.1?report=fasta
BS002364.1	Japan	1/15/2022	BA.11	GT-S2	https://www.ncbi.nlm.nih.gov/nuccore/BS002364.1?report=fasta
BS002365.1	Japan	1/15/2022	BA.11	GT-S2	https://www.ncbi.nlm.nih.gov/nuccore/BS002365.1?report=fasta
BS002435.1	Japan	1/14/2022	BA.11	GT-S3	https://www.ncbi.nlm.nih.gov/nuccore/BS002435.1?report=fasta
BS002436.1	Japan	1/14/2022	BA.11	GT-S2	https://www.ncbi.nlm.nih.gov/nuccore/BS002436.1?report=fasta
BS002437.1	Japan	1/14/2022	BA.11	GT-S2	https://www.ncbi.nlm.nih.gov/nuccore/BS002437.1?report=fasta
BS002438.1	Japan	1/14/2022	BA.11	GT-S2	https://www.ncbi.nlm.nih.gov/nuccore/BS002438.1?report=fasta
BS002439.1	Japan	1/14/2022	BA.11	GT-S2	https://www.ncbi.nlm.nih.gov/nuccore/BS002439.1?report=fasta
BS002408.1	Japan	1/13/2022	BA.11	GT-S3	https://www.ncbi.nlm.nih.gov/nuccore/BS002408.1?report=fasta
BS002409.1	Japan	1/13/2022	BA.11	GT-S3	https://www.ncbi.nlm.nih.gov/nuccore/BS002409.1?report=fasta

BS002410.1	Japan	1/13/2022	BA.11	GT-S3	https://www.ncbi.nlm.nih.gov/nuccore/BS002410.1?report=fasta
BS002411.1	Japan	1/13/2022	BA.11	GT-S3	https://www.ncbi.nlm.nih.gov/nuccore/BS002411.1?report=fasta
BS002412.1	Japan	1/13/2022	BA.11	GT-S1	https://www.ncbi.nlm.nih.gov/nuccore/BS002412.1?report=fasta
BS002395.1	Japan	1/12/2022	BA.11	GT-S1	https://www.ncbi.nlm.nih.gov/nuccore/BS002395.1?report=fasta
BS002396.1	Japan	1/12/2022	BA.11	GT-S1	https://www.ncbi.nlm.nih.gov/nuccore/BS002396.1?report=fasta
BS002397.1	Japan	1/12/2022	BA.11	GT-S2	https://www.ncbi.nlm.nih.gov/nuccore/BS002397.1?report=fasta
BS002401.1	Japan	1/12/2022	BA.1	GT-S3	https://www.ncbi.nlm.nih.gov/nuccore/BS002401.1?report=fasta
BS002402.1	Japan	1/12/2022	BA.11	GT-S1	https://www.ncbi.nlm.nih.gov/nuccore/BS002402.1?report=fasta
BS002528.1	Japan	1/11/2022	BA.11	GT-S2	https://www.ncbi.nlm.nih.gov/nuccore/BS002528.1?report=fasta
BS002529.1	Japan	1/11/2022	BA.11	GT-S2	https://www.ncbi.nlm.nih.gov/nuccore/BS002529.1?report=fasta
BS002530.1	Japan	1/11/2022	BA.11	GT-S2	https://www.ncbi.nlm.nih.gov/nuccore/BS002530.1?report=fasta
BS002531.1	Japan	1/11/2022	BA.11	GT-S3	https://www.ncbi.nlm.nih.gov/nuccore/BS002531.1?report=fasta
BS002532.1	Japan	1/11/2022	BA.11	GT-S3	https://www.ncbi.nlm.nih.gov/nuccore/BS002532.1?report=fasta

Table 1b SARS-CoV-2 GENEIDO Analysis January 2022 - Japan